Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Buys Back Xmark Warrants, Retires Debt

NEW YORK, Jan. 17 (GenomeWeb News) - Clinical Data has bought back a total of 130,000 warrants from Xmark Opportunity Fund for total cash consideration of $130,000, the company said today. Each repurchased warrant carried the right to buy Clinical Data common stock at a price of $28.50 per share.


The repurchase opportunity was the result of the diagnostic company's retiring a $4.5 million dollar note previously issued to Xmark, said Clinical Data chief financial officer Mark Shooman in a statement.


The warrants and the debt were assumed by Clinical datae in its October 2005, $56 million all-stock purchase of Genaissance.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.